skip to Main Content

PRESS RELEASES

Canntab Therapeutics Limited

For immediate release

2020_09_21

CANNTAB GRANTED 1st US PATENT COVERING MULTI-LAYER (BI-LAYER) TABLETS

TORONTO, September 21st, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce that, pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab, titled “Modified Release Multi-Layer Tablet Cannabinoid Formulations.” The term of the patent expires on March 15, 2038.

Larry Latowsky, CEO of Canntab said “this is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future. This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab’s position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids.

The patent granted is for Canntab’s bi-layer or multi-layer tablets consisting of both Instant Release (“IR”) and Extended Release (‘XR”) formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.

Canntab believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing. Canntab believes and intends to prove greater bioavailability through a blood level study at a 3rd party Clinical Research Organization (CRO). In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab is able to provide extended release formulations making it the clear delivery choice for doctors, patients or the average consumer.

“Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products. As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications” continued Latowsky.

In addition, Canntab is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntab will be using a derivative of these formulations for its clinical trial with Dr. Donald Garbuz from the University of British Columbia and as previously released in December 2018. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during post-operative pain management.

This issued patent covers Canntab’s modified release pharmaceutical compositions and more specifically compositions comprising cannabinoids and a process for preparation thereof as well as methods for administering the compositions to human users. The compositions may contain a combination of ingredients in proportions calculated to achieve therapeutic effect.

Canntab has filed applications for 13 patents in Canada and the United States that cover a range of processes and formulations that it uses to create its precision oral-delivery hard tablets, the future of medical cannabis. These patents include Canntab’s proprietary nano-emulsification technology, granulation process, methods of manufacturing and covers its full line of precision oral-delivery hard tablets including instant (immediate) release tablets, extended release tablets, oral dissolvable tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Long referred to as Cannabis 3.0 by the Company, Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in pharmacies around the world. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes License, a Cannabis Research License, and an Industrial Hemp License from Health Canada.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Larry Latowsky
Chief Executive Officer
+1 833 301-3812
larry@canntab.ca

Richard Goldstein
Chief Financial Officer
+1 833 301-3812
richard@canntab.ca

Frank Candido
Business Development and Investor Relations
514-969-5530
Frank@canntab.ca

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release contains forward-looking statements. Forward-looking statements are statements that contemplate activities, events or developments that the Company anticipates will or may occur in the future. Forward-looking statements in this press release include those regarding the Company’s patent being used to successfully treat nicotine, alcohol, cannabis, opioid and other forms of addiction, and the Company’s plan to rely on the patent and additional patents issued in the future to develop strategic partnerships and alliances and efforts to secure worldwide distribution. These forward-looking statements reflect the Company’s current expectations based on information currently available to management and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those projected. Readers should refer to the risk disclosure included from time-to-time in the documents the Company files on SEDAR, available at www.sedar.com. Although the Company believes that the assumptions inherent in these forward-looking statements are reasonable, they are not guarantees of future performance and, accordingly, they should not be relied upon and there can be no assurance that any of them will prove to be accurate. Finally, these forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update them except as required by applicable law.

Canntab Therapeutics Limited

For immediate release

2020_08_21

CANNTAB ANNOUNCES PLANNED PURCHASES OF CANNABIS PROCESSING EQUIPMENT AND LEASEHOLD IMPROVEMENTS

TORONTO, August 21st, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has entered into a binding asset purchase agreement to acquire certain cannabis-processing equipment and leasehold improvements (the “CMAX Assets”) located at its 223 Riviera Drive, Markham, Ontario facility from CMAX Technologies Inc. (“CMAX”), a related party of the Company for $1,018,000 (the “CMAX Transaction”).

The purchase price of the CMAX Assets was based upon third party valuations ordered by Canntab. The purchase price will be satisfied through the issuance of 1,996,078 common shares of the Company (the “Common Shares”) at a deemed price of $0.51 per Common Share. A deposit of 200,000 Common Shares will be paid to CMAX within 14 days of the execution of the purchase agreement.

The Company has also entered into a binding asset purchase agreement with Pharmagenerics Solutions Inc. (“Pharma”) to purchase cannabis-processing equipment (the “Pharma Assets”) owned by Pharma (the “Pharma Transaction”). The purchase price of the Pharma Assets of $300,000 will be satisfied through the issuance of 588,235 Common Shares at a deemed price of $0.51 per Common Share. Joshi Laxminarayan, Chief Scientific Officer of the Company is the sole officer, director and shareholder of Pharma. The binding asset purchase agreement replaces a letter of intent that Mr. Laxminarayan and the Company had entered into in March of 2020, and the deemed price of the Common Shares issuable to Mr. Laxminarayan were determined by reference to then-current closing price of $0.50 per share. This corresponds as well to the $0.50 unit financing completed at the same time.

The CMAX Transaction will constitute a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”), but is otherwise exempt from the formal valuation and minority approval requirements of MI 61-101. The CMAX Transaction has been approved by the independent director of the Company. Richard Goldstein, Chief Financial Officer and Director of the Company is a shareholder and the sole director and officer of CMAX Technologies Inc. In addition, Jeffrey Renwick, Chief Executive Officer and Director of the Issuer, Barry Polisuk, Secretary and Director of the Issuer, and Joshi Laxaminarayan , Chief Scientific Officer of the Issuer are shareholders of CMAX Technologies Inc. Mr. Polisuk holds 1.44% of CMAX’s outstanding common shares, Mr. Goldstein holds 11.19%, Mr. Renwick holds 38.83% and Mr. Laxminarayan holds 18.04%. The closing of the CMAX Transaction and the Pharma Transaction are subject to customary closing conditions contained in transactions of this nature.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

Richard Goldstein

Chief Financial Officer

+1 833-301-3812

richard@canntab.ca

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including regulatory approvals necessary to enable to the Company to commence full scale manufacturing and distribution, that the consultant will agree to the cancellation of its existing warrants, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation  that another cannabis producer will bring timed-release cannabinoid hard pills to market in Canada and foreign jurisdictions prior to the Company, that the Company will fail to secure additional funding, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

Canntab Therapeutics Limited

For immediate release

2020_08_19

CANNTAB APPOINTS LARRY LATOWSKY AS CEO

TORONTO, August 19th, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Larry Latowsky as CEO effective immediately.

Originally appointed as an Advisor to the Company, it was mutually decided that Mr. Latowsky’s extensive experience and connections in wholesale, retail and direct to consumer pharmaceutical industries would be an essential ingredient to the operations of the Company and accordingly the board of directors decided to appoint Larry as CEO.

Canntab had originally announced that Mr. Latowsky would be appointed to the Board as Executive Chairman, however, the board of directors unanimously determined that he would be much more valuable to the Company in a full-time role as CEO and will navigate Canntab’s future growth.

Jeff Renwick, co-founder of Canntab, will assume the role of President and Head of Manufacturing while remaining an integral member of Canntab’s Board of Directors.

Mr. Latowsky has held a number of leadership positions throughout his career including being President and CEO of Drug Trading Company and President and CEO of Katz Group Canada overseeing the largest network of pharmacy retailers in Canada operating as Rexall, Pharmaplus, IDA and Guardian Drugstores. Mr. Latowsky also led Propharm Technology and DC Labs a vertical manufacturing and packaging division of pharmaceuticals and over the counter drug store product. Mr. Latowsky, a graduate of the University of Toronto Rotman Business School and Institute of Corporate Directors of Canada program, has served on many profit and non-profit Boards including being Chairman of the Board for Well.ca, one of Canada’s leading E-commerce companies. Mr. Latowsky’s experience is a unique blend of traditional retail bricks and mortar, distribution, manufacturing and e commerce/internet-based marketing and sales.

“I am very excited to join Canntab on a full-time basis. Canntab’s IP and product offerings are truly unique. Jeff Renwick and his production team’s knowledge and experience in the production of pharmaceutical products is very impressive. There is a tremendous opportunity for Canntab’s products both within Canada and worldwide. I would like to thank Jeff Renwick, Richard Goldstein and the entire Canntab board of directors for trusting me with this important role. I have no doubt that together we will continue to build a successful business which will benefit all of our shareholders” explained Larry Latowsky.

“Making room for a person of Larry’s experience was an easy decision. Our commitment is to build a world-class company and that begins by attracting world-class talent. We decided after working closely with Larry that his experience would be best suited to a daily role leading our company, especially in the crucial areas of sales, marketing and distribution with the tremendous growth opportunities which lie ahead” stated Jeff Renwick President and Co-Founder of Canntab.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada. Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in the United States. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

President & Head of Production

+1 833-301-3812

jeff@canntab.ca

 

Richard Goldstein

Chief Financial Officer

+1 833-301-3812

richard@canntab.ca

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including regulatory approvals necessary to enable to the Company to commence full scale manufacturing and distribution, that the consultant will agree to the cancellation of its existing warrants, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation  that another cannabis producer will bring timed-release cannabinoid hard pills to market in Canada and foreign jurisdictions prior to the Company, that the Company will fail to secure additional funding, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

Canntab Therapeutics Limited

For immediate release

2020_06_02

CANNTAB AND MEDIPHARM LABS ENTER INTO A WHOLESALE TABLET PURCHASE AGREEMENT

TORONTO, JUNE 2nd, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it is today beginning production of its instant release tablets and has already entered into its first purchase agreement with MediPharm Labs (“MediPharm”) (TSX:LABS)(OTCQX: MEDIF)(Deutsche Borse: MLZ), a global leader in pharma quality cannabinoid based products.

Canntab received its first order under the agreement today, and the value of the full agreement will exceed $1 million. Orders under the agreement will be composed of a mix of Canntab’s proprietary instant release tablets delivering THC, CBD and a combination of THC/CBD in 12 different strengths. MediPharm will purchase and distribute cannabis products on a non-exclusive basis across Canada, through licensed provincial dispensaries.

The exact value of shipments under the agreement will be determined no later than June 30, 2020 and will depend on the final concentrations of Canntab’s instant release tablets chosen by MediPharm.

Canntab has already filed its 60 day notice for approval to sell this line of products with Health Canada and expects that its tablets will be available for sale in the early summer. Canntab is currently the only company in Canada capable of delivering THC, CBD and/or any combination THC/CBD in pharmaceutical grade tablets or hard pills.

Jeff Renwick, CEO of Canntab said “we are very excited and pleased to have achieved this major milestone in our short history as a company. We are especially pleased to have accomplished this major milestone in the face of the Covid-19 Pandemic which has caused major uncertainty and disruption in  world markets, including, Canada. Canntab has continued to work diligently to build shareholder value during this crisis as we are designated an essential business. Signing our first purchase order with a quality partner having a global reach such as MediPharm is simply the tip of the iceberg for Canntab.”.

“We’re pleased to be working with Canntab who are leading the way in manufacturing innovative cannabis based tablets,” said Pat McCutcheon, Chief Executive Officer, MediPharm. “With MediPharm’s robust supply chain and established distribution channels, we are excited to roll out novel high quality tablet products in the coming months to medical and adult-use consumers across Canada.”

Canntab has filed 13 patents in Canada and United States that cover a range of processes and formulations that it uses to create its precision oral delivery hard tablets, the future of medical cannabis. These patents include Canntab’s proprietary nano-emulsification technology, granulation process, methods of manufacturing, and covers its full line of precision oral delivery hard tablets including; Instant (Immediate) Release Tablets, Extended Release Tablets, Oral Dissolvable Tablets and Bi-Layered (Modified Release) Tablets. Canntab has also filed a patent for an exclusive formulation of THC and CBD for the treatment of opioid addiction treatment therapy.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability. The future of medical cannabinoid solutions.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

 

Jeffrey Renwick

Chief Executive Officer

+1 833-301-3812

jeff@canntab.ca

 

Richard Goldstein

Chief Financial Officer

+1 833-301-3812

richard@canntab.ca

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including regulatory approvals necessary to enable to the Company to commence full scale manufacturing and distribution, that the consultant will agree to the cancellation of its existing warrants, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation  that another cannabis producer will bring timed-release cannabinoid hard pills to market in Canada and foreign jurisdictions prior to the Company, that the Company will fail to secure additional funding, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

Canntab Therapeutics Limited

For immediate release

2020_05_15

CANNTAB APPOINTS JOSHI LAXMINARAYAN AS CHIEF SCIENTIFIC OFFICER

TORONTO, May 15th, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the appointment of Joshi Laxminarayan as Chief Scientific Officer (CSO). In his role as CSO, Mr. Laxminarayan will be responsible for directing Canntab’s strategic research and partnership program, and overseeing the Company’s ongoing manufacturing and distribution operations.

Mr. Laxminarayan is a pharmaceutical scientist with a successful history of bringing to market a number of pharmaceutical drugs throughout a career spanning over 25 years. Mr. Laxminarayan began his career in  India, as a bench chemist, and most recently acted in a consultant role to the Company, as Director of Quality Assurance & Quality Control, where he assisted with the research and development needed to formulate the Company’s current product line. His expertise in nano emulsion, extended release, and poorly soluble drug development, has played a crucial role in the Company’s research and development with respect to cannabis oil inputs.

“Joshi has played an integral part in helping Canntab strengthen its competitive position and relevance, and distinguish itself in the pharmaceutical industry. His appointment as CSO is expected to evolve as we continue manufacturing, into a position where he can oversee not only our ongoing Research & Development, but also our day to day manufacturing and distribution operations,” explains Jeff Renwick, Co-founder and CEO of Canntab. Mr. Renwick continues, “As Canntab enters the next phase  of its growth,  Mr. Laxminarayan will be invaluable to our continued success, driving us closer to our goal of being the world leader in solid oral dose therapeutic cannabis solutions.”

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 833-301-3812

jeff@canntab.ca

Cautionary Statements

 Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

 Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially, and are based on management’s current beliefs, assumptions, and expectations.  While Canntab considers these beliefs, assumptions and expectations to be reasonable and based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

CANNTAB TO PRESENT AT THE CANACCORD GENUITY 2020 VIRTUAL CANNABIS CONFERENCE

TORONTO, May 11th, 2020/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Mr. Larry Latowsky , Special Advisor and future Executive Chairman of the Board of Directors of the Company (pending Health Canada approval), will present via webcast at the Canaccord Genuity 4th Annual Cannabis Conference, on Tuesday, May 12, 2020 , at 9:20 a.m. (EST) .
Mr. Latowsky’s presentation is expected to discuss, among other things, the Company’s top priorities, and strategic plans for the future.
“Many companies solicited my support and directorships, but I joined Canntab half a year ago because of my belief in Canntab’s business model and its distinctive product offerings. Canntab’s medical cannabis solutions, which will be critical to the adoption of cannabinoids by the medical community, place Canntab in a unique position to execute on significant opportunities that will generate sustainable value for all stakeholders,” explains Larry Latowsky , Special Advisor and future Executive Chairman of the Board, pending Health Canada approval.
Mr. Latowsky brings decades of experience in the manufacturing, wholesale and distribution of pharmaceutical and nutraceutical products, having previously served as the President and CEO of Drug Trading Co., and Katz Group Canada, the parent company of, among others, Rexall Pharmaplus.
The webcast of the Company’s presentation will be available at:
About Canntab Therapeutics
Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.
Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.
Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.
Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
For further information:
Canntab Therapeutics Limited
Jeffrey Renwick
Chief Executive Officer
+1 833-301-3812
Richard Goldstein
Chief Financial Officer
+1 833-301-3812

 

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including receipt of Health Canada approval and other regulatory approvals necessary to enable to the Company to manufacturing and distribution, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with Health Canada not approving the Company’s application for Notice of New Cannabis Products, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

 

CANNTAB CLOSES FINAL TRANCHE OF PRIVATE PLACEMENT FOR AGGREGATE PROCEEDS OF $3.7M

TORONTO, March 16th, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that it has closed the final tranche of its previously announced non-brokered private placement (the “Private Placement“) by issuing 1,291,000 units (“Units“) at a price of $0.50 per Unit for gross proceeds of $645,500. Together with the funds raised under the first tranche of the Private Placement, the Company has received total gross proceeds of $3,725,500 under the Private Placement.

“With the gross proceeds from this financing we now have the capital to completely implement our business plan. “Raising significant equity during these extraordinary market conditions coupled with the inherent recent challenges in the Cannabis space in particular is a testament to the level of interest which exists in the future of Canntab”” explains Richard Goldstein, Co-founder & Chief Financial Officer of Canntab. Mr. Goldstein concludes, “we began as a pharmaceutical company more than a decade ago, and we will continue to operate as a pharmaceutical company producing the most advanced medical cannabis solutions.”  

Closing the Final Tranche

The Private Placement was previously announced on February 6, 2020.  Pursuant to the closing of both tranches of the Private Placement, Canntab has issued 7,451,000 Units for gross proceeds of $3,725,500. Each Unit consists of one common share (a “Common Share”) and one full warrant (a “Warrant”) to acquire an additional common share at a price of $0.75 per share for a period of 24 months.

In connection with the Private Placement, the Company paid fees to a syndicate of registrants that were comprised of cash fees of $228,095 and issued 456,190 finder’s warrants, which each entitle the holder thereof to purchase one Common Share at a price of $0.50 for a period of 24 months.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 833-301-3812

jeff@canntab.ca

 

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including receipt of Health Canada approval and other regulatory approvals necessary to enable to the Company to manufacturing and distribution, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with Health Canada not approving the Company’s application for Notice of New Cannabis Products, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

 

Canntab Therapeutics Limited

For immediate release

2020_03_06

CANNTAB ANNOUNCES REPLACEMENT OF ADVISOR WARRANTS AND INTENTION TO APPOINT LARRY LATOWSKY AS DIRECTOR AND EXECUTIVE CHAIRMAN OF THE BOARD

TORONTO, March 6, 2020 /CNW/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab”), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it intends to issue 500,000 common share purchase warrants (the “Replacement Warrants”) to Larry Latowsky and that, subject to Health Canada approval, Canntab intends to appoint Larry Latowsky as a Director and Executive Chairman of the Board.

Each Replacement Warrant will be exercisable at a price of $0.60 per share until March 4, 2025. Issuance of the Replacement Warrants is subject to Mr. Latowsky’s agreement to cancel an equivalent number of common share purchase warrants exercisable at a price of $1.00 per share. The Replacement Warrants will be subject to a vesting schedule, with 100,000 vesting on the date of issuance, 200,000 vesting on the first anniversary thereof, and 100,000 vesting on each of the second and third anniversaries of issuance.

Mr. Latowsky is in the process of obtaining Health Canada approval to his planned appointment as Director and Executive Chairman of the Company. “Subject to approval of Health Canada, it is Canntab’s intent to have Mr. Latowsky become its Executive Chairman of the Board and lead the commercialization strategy with great emphasis on distribution channels around the world” says Richard Goldstein, Co-Founder and Chief Financial Officer of Canntab. Mr. Latowsky graduated from the Toronto ICD-Rotman Directors Education Program at the Rotman School of Management in May of 2011.

“I am excited to be part of the Canntab team. Over the past several months as an advisor I have realized my decision to associate with the right company in this space has been confirmed.” explains Larry Latowksy. Mr. Latowsky continues, “The experienced people, the cost-conscious philosophy and approach, the utilization of resources and above all the unique differentiated offering is in my opinion a balanced recipe for success for all stakeholders. As an experienced director and chair I am very excited to lead Canntab as executive chairman to guide strategic direction that will ultimately lead to increasing shareholder value.”

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability. The future of medical cannabinoid solutions.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including regulatory approvals necessary to enable to the Company to commence full scale manufacturing and distribution, that the consultant will agree to the cancellation of its existing warrants, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, that Health Canada will not approve of Larry Latowsky’s appointment as a Director of the Company, that Larry Latowsky will not agree to the cancellation of his existing warrants,  that another cannabis producer will bring timed-release cannabinoid hard pills to market in Canada and foreign jurisdictions prior to the Company, that the Company will fail to secure additional funding, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

 

Canntab Therapeutics Limited

For immediate release

2020_03_02

CANNTAB RECEIVES HEALTH CANADA LICENCE AND CLOSES $3.08M OFFERING

  • Receives its Cannabis Standard Processing & Sales for Medical Purposes Licence
  • Closes first tranche of its non-brokered private placement for gross proceeds of $3.08M
  • Proceeds of the financing will be used to begin full scale manufacturing at its Markham facility, and to launch products across Canada and the United States

TORONTO, March 2nd, 2020 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that on Friday, February 28th, 2020 it successfully  received its Cannabis Standard Processing & Sales for Medical Purposes Licences from Health Canada, and that it has closed the first tranche (the “First Tranche”) of its non-brokered private placement offering (the “Private Placement”) for total gross proceeds of $3,080,000.

“With the licensing and financing, we are now in a position to move into full scale manufacturing and distribution of our next generation of biopharmaceutical cannabinoid solutions. We plan to roll-out new brands and products for sale, starting this summer,” explains Jeff Renwick, Chief Executive Officer at Canntab. “Canntab intends to be the first to bring timed-release cannabinoid hard pills to market in Canada,” concludes Mr. Renwick.

Closing of First Tranche

The Private Placement was previously announced on February 6, 2020.  Pursuant to the closing of the First Tranche, Canntab has issued 6,160,000 units of the Company (“Units”) at a price of $0.50 per Unit for gross proceeds of $3,080,000. Each Unit consists of one common share (a “Common Share”) and one full warrant (a “Warrant”) to acquire an additional common share at a price of $0.75 per share until February 28th, 2022. The Company anticipates closing an additional tranche of the Private Placement to raise total gross proceeds of up to $4,000,000.

In connection with the Private Placement, the Company paid commissions to a syndicate of registrants that were comprised of cash finder’s fees of $113,260 (“Cash Finder’s Fees”) and issued 226,520 finder’s warrants (“Finder’s Warrants”). The Finder’s Warrants each entitle the holder thereof to purchase one Common Share at a price of $0.50 for a period of 24 months.

Several directors, officers and other insiders as defined in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101“), participated in the Private Placement, either directly or indirectly, and First Republic Capital Corporation, an exempt market dealer of which Richard Goldstein, the CFO and a director of the Company, is also a significant shareholder and the President, received a portion of the Cash Finder’s Fees and Finder’s Warrants in connection with the Private Placement, therefore the Private Placement constitutes a “related party transaction” within the meaning of MI 61-101. In its consideration and approval of the Private Placement, the board of directors of the Company determined that the Private Placement is exempt from the formal valuation and minority approval requirements of MI 61-101 on the basis that the fair market value of the Private Placement, including the Cash Finder’s Fees and Finder’s Warrants paid to First Republic Capital Corporation, to related parties does not exceed 25% of the market capitalization of the Company, in accordance with Sections 5.5 and 5.7 of MI 61-101. The Company did not file a material change report more than 21 days before the closing of the Private Placement as the details of the Private Placement, and the confirmation of insider participation in the Private Placement, was not definitively known to the Company until the date of the closing of the Private Placement and the board of directors determined that it was in the best interests of the Company to close the Private Placement as soon as practicable.

About Canntab Therapeutics

Canntab Therapeutics is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.  Canntab’s proprietary hard pill cannabinoid formulations provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies. These will include the following formulations: once a day and extended release, both providing an accurate dose and improved shelf stability. The future of medical cannabinoid solutions.

Canntab holds a Cannabis Standard Processing & Sales for Medical Purposes Licence, a Cannabis Research Licence, and an Industrial Hemp Licence from Health Canada.

Additionally, Canntab through its wholly owned American subsidiary is in the process of establishing a CBD manufacturing and distribution business in Florida, USA.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 833-301-3812

jeff@canntab.ca

 

Cautionary Statements

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including receipt of Health Canada approval and other regulatory approvals necessary to enable to the Company to commence full scale manufacturing and distribution, that another producer of cannabis products will not bring timed-release cannabinoid hard pills to market in Canada prior to the Company, and that the Company will close one or more additional tranches of the Private Placement, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business.  While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with Health Canada not approving the Company’s application for Notice of New Cannabis Products, that another cannabis producer will bring timed-release cannabinoid hard pills to market in Canada prior to the Company, that the Company will fail to secure additional funding under the Private Placement, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

 

Canntab Therapeutics Limited

For immediate release

2020_02_24

CANNTAB AWARDED HEALTH CANADA CANNABIS RESEARCH LICENCE

TORONTO, February 24th, 2020/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that Health Canada has granted the Company a Cannabis Research Licence for the purpose of continuing research and development of the Company’s growing line of next generation medical cannabis solutions at the Company’s Markham Ontario Facility.

Canntab intends, following receipt of a Standard Processing Licence and Sale for Medical Purposes Licence from Health Canada (the “Additional Licences”), to produce various hard pill oral delivery formulations including extended release, instant release, and bi-layered hard pills that provide patients and practitioners with a highly bioavailable medical solution with accurate dosing. The Additional Licences will enable Canntab to submit Notice of New Cannabis Products (NNCP) to Health Canada.
“Our Cannabis Research Licence will allow us to be prepared for when we receive our Standard Processing Licence and Sale” for Medical Purposes Licence, which we expect to receive shortly, by allowing us to do research and testing. Once we obtain our Standard Processing Licence and Sale for Medical Purposes Licence, we will have products ready for distribution and sale, explains Jeff Renwick, co-founder and CEO of Canntab. Mr. Renwick continues, “our facility is fully built-out and we are excited to prepare our final formulations for submission. We are equally excited with the prospect of continuing research and development in full force at our Markham facility, beginning with our proprietary Oral Dissolvable Tablet formulations which enter through the buccal cavity in the patient’s mouth.”
About Canntab Therapeutics
Canntab Therapeutics Ltd. is a Canadian company with operations in Canada. Canntab has also established a wholly owned US subsidiary through which we will operate our business in the United States. Upon our receipt of LP Status from Health Canada, Canntab will begin full-scale manufacturing of its suite of precision oral dose products that are unavailable elsewhere in the marketplace, namely, formulations in multiple doses and time release combinations. Additionally, Canntab through its wholly owned American subsidiary operate Canntab’s manufacturing and distribution business in the United States, with the Company’s partner Exactus Inc.
Canntab’s proprietary hard pill medical cannabis formulations will provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies.
Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
Cautionary Statements
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or negatives of these terms and similar expressions. Forward-looking statements are based on certain assumptions, including successful receipt of the Additional Licences, the approval by Health Canada of the Company’s Notice of New Cannabis Products, and general business, economic, competitive, political and social uncertainties will not prevent the Company from conducting its business. While Canntab considers these assumptions to be reasonable, based on information currently available, they are inherently subject to significant business, economic and competitive uncertainties and contingencies and they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including without limitation, risks associated with Health Canada not approving the Company’s application for a new licence or Notice of New Cannabis Products, general economic conditions, adverse industry events, marketing costs, loss of markets, future legislative and regulatory developments, the inability to access sufficient capital on favourable terms, the medical and recreational cannabis industry in Canada in general, income tax and regulatory matters, the ability of Canntab to execute its business strategies, competition, crop failure, currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ from those anticipated. Forward-looking statements are not guarantees of future performance. Except as required by law, Canntab disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, events or otherwise. Forward- looking statements contained in this news release are expressly qualified by this cautionary statement.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 289.301.3812

jeff@canntab.ca

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2020_02_06

CANNTAB ANNOUNCES NON-BROKERED PRIVATE PLACEMENT

TORONTO, February 6th, 2020/ – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it is launching a private placement (the “Private Placement”) of up to $2.5 million of units (“Units”), subject to the Company’s over-allotment option to increase the size of  the Private Placement by up to an additional $1.5 million, at a price of $0.50 per Unit, with each Unit consisting of one common share and one full warrant to acquire an additional common share at a price of $0.75 per share for a period of two years. Canntab expects to close the Private Placement on or before February 20th, 2020.

The proceeds from the Private Placement will be used for:

  • Canntab’s expansion through its wholly owned US subsidiary Canntab USA, Inc. into the State of Florida jointly with Exactus Inc. for the manufacture of a CBD hard pill (non-THC) in formulations for sale and distribution across the United States.
  • A trial with the University of British Columbia to research the effect of opioid sparing high formulation with Canntab’s bi-layered CBD/THC controlled release formulations for post-operative pain care.
  • Clinical 3-way crossover blood level study to further the Company’s research of its solid oral dose formulations, including extended release, immediate release, and multi-particulate formulations.
  • Expansion of the Company’s facility in Markham, Ontario Canada.
  • Chemistry analysis and third-party testing of products for New Cannabis Product applications for Health Canada.
  • Manufacturing inputs needed to build inventory of products for sale and distribution.
  • General working capital purposes.

“We accomplished the goals that we set out for ourselves almost 2 years ago, and we are now at the doorstep for the full-scale manufacturing and distribution of our innovative medical cannabis solutions. The proceeds from this private placement will strengthen our balance sheet (which remains without any long term debt) and will allow us to take advantage of the opportunities we’ve cultivated, and will establish Canntab as the premiere solution for medical cannabis in Canada, and across the world”, said Jeffrey Renwick, CEO of Canntab.

In connection with the Private Placement, the Company may pay finder fees of up to 7% of the gross proceeds and issue finder warrants of up to 7% of the Units sold, and each being exercisable for one common share at a price of $0.50 for a period of two years.

About Canntab Therapeutics

On December 23rd, Health Canada confirmed receipt of Canntab’s Site Evidence Package, to begin the final process for Canntab to obtain LP Status for its Markham, Ontario Facility.

Canntab Therapeutics Ltd. is a Canadian company with operations in Canada and shortly also in the United States. Upon our receipt of LP Status from Health Canada, Canntab will begin full-scale manufacturing of its suite of precision oral dose products that are unavailable elsewhere in the marketplace, namely, formulations in multiple doses and time release combinations. Canntab has established a wholly owned American subsidiary which will operate Canntab’s manufacturing and distribution business in the United States. Canntab’s proprietary hard pill medical cannabis formulations will provide doctors, patients and consumers with medical grade solutions which incorporate all the features one would expect from any prescription or over the counter medication sold in Canadian pharmacies.

Additionally, Canntab has applied for its Cannabis Research Licence in Canada. The research licence will likely be acquired before Canntab obtains Licensed Producer status and will allow Canntab to receive oil, and to begin preparing product submissions to Health Canada, and to purchase machines for full scale manufacturing.

Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Forward Looking Information

 This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of the Company, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the expected completion of the Private Placement and the timing thereof, the anticipated granting of Licensed Producer Status to the Company by Health Canada, the anticipated granting Cannabis Research Licence to the Company by Health Canada, the Company’s intention to commence full-scale manufacturing of its suite of precision oral dose products, and its intention to operate a manufacturing and distribution business in the United States.

Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company’s control. These risks, uncertainties and assumptions include, but are not limited to the Company being able to source sufficient investors to complete the Private Placement on the timeline indicated or at all, Health Canada finding the Company in compliance with all requirements needed to be granted Licensed Producer Status and a Cannabis Research Licence, the Company being able to commence operations, including full-scale manufacturing of its suite of precision oral dose products, and its intention to operate a manufacturing and distribution business in the United States, following the Private Placement and receipt of all applicable licences.  Accordingly, readers should not place undue reliance on the forward- looking statements and information contained in this news release. The Company does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

For further information:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 289.301.3812

jeff@canntab.ca

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019-12_23

Canntab Submits Site Evidence Package to Health Canada to Obtain LP Status

  • The final step to obtain a licence to process Canntab’s cannabis hard pill formulation, at its fully built out Markham, Ontario facility.
  • Retains Larry Latowsky, former CEO of Katz Group Canada and its flagship holding Rexall, as an advisor in order to strengthen Canntab’s commercialization efforts.

TORONTO, May 21, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab”), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces today the submission of the Company’s Site Evidence Package to Health Canada for approval of their Licence Producer Status (Processing-Standard, Federal Sales-Medical). The submission marks the final step required to obtain a licence to process cannabis at the facility, pending Health Canada review and approval.

The Company’s facility, located in Markham, Ontario, is designed and fully equipped to accommodate all manufacturing necessary to produce Canntab’s pharmaceutical grade cannabis hard pill formulations (solid oral dosage forms), which the Company believes is the future of medical cannabis. The formulations are comprised of various combinations of THC and CBD and will come in dosages of 2.5 mg, 5 mg and 10 mg, in extended release, instant release, and bi-layered solutions. Ongoing research and development into individual cannabinoids is expected to contribute additional formulations and dosage forms for future production.

“After almost a year and a half of consulting, designing, and building, we have reached an important milestone in Canntab’s business development, we have submitted our final evidence package to Health Canada for review,” explains Jeff Renwick, co-founder and CEO of Canntab. Mr. Renwick continues, “With our licence, we will be able to manufacture hundreds of thousands of hard pills a day, in a growing variety of formulations that are unique in the marketplace.”

Retention of Larry Latowsky as an Advisor

As the Company pivots from development to manufacturing, marketing and distribution, the Company has retained the expertise of Larry Latowsky as advisor. Mr. Latowsky has extensive experience and contacts in the wholesale, retail and direct to consumer pharmaceutical industries, having previously been the President and CEO of Drug Trading Co., and Katz Group Canada, the parent company of Rexall, Pharmaplus, IDA, Guardian, Medicine Shoppe, Herbies, Propharm Technology, and Druggists Corporation (DC Labs). In connection with Mr. Latowsky’s engagement, the Company has granted him an aggregate of 500,000 common share purchase warrants, each entitling the holder thereof to purchase one common share of the Company at a price of $1.00 per share. The warrants vest over a period of three years.

Larry Latowsky says, “I’m excited to be a part of Canntab’s business as they move into manufacturing and marketing. Their unique and patent pending product offerings and full-scale manufacturing capability, provide an excellent opportunity for me to leverage my skills and network for the purpose of distributing and licensing Canntab’s medical solutions to a broad market.”

Canntab’s Extensive IP Portfolio – At the Core of Our Value Proposition

Canntab has filed 13 patents in Canada and United States that cover a range of processes and formulations needed to create the Company’s hard pill formulations, including instant release, extended release, and bi-layered solutions.

In August the International Preliminary Report on Patentability (IPRP) indicated a positive finding of patentability for Canntab’s Instant Release Cannabidiol Formulation, meaning that, in their opinion, the Company’s formulation is not only patentable but also novel, non-obvious and useful.

About Canntab Therapeutics

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace, formulated in multiple doses and time release combinations. Canntab’s proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Additionally, Canntab has applied for its Cannabis Research Licence in Canada. The research licence will likely be acquired before Canntab obtains Licensed Producer status, which will allow the Company to receive oil, and to begin preparing product submissions to Health Canada, and machines for full scale manufacturing. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Forward Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of the Company, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the anticipated granting of Licensed Producer Status to the Company by Health Canada, the Company’s projected yield of production of pharmaceutical grade cannabis hard pill formulations; and the Company’s ability to create additional formulations and dosage forms for future production. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company’s control. These risks, uncertainties and assumptions include, but are not limited to Health Canada finding the Company in compliance with all requirements needed to be granted Licensed Producer Status; the Company having the necessary capacity to produce the projected yield of pharmaceutical grade cannabis hard pill formulations as well as the Company being able to create additional formulations for future production; demand for the pharmaceutical grade cannabis hard pills not being less than expected by management; and the costs of production not being greater than expected by management. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

FOR ADDITIONAL INFORMATION PLEASE CONTACT:
Canntab Therapeutics Limited
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019_11_20

CANNTAB ACHIEVES KEY MILESTONE: CANNTAB ENTERS INTO SUPPLY & DISTRIBUTION AGREEMENTS WITH EXACTUS FOR THE PURCHASE OF HEMP-DERIVED CBD OIL AND THE DISTRIBUTION OF CANNTAB’S HARD PILL FORMULATIONS IN THE UNITED STATES
  • Canntab will manufacture its hard pill formulations (made from CBD and other hemp derivatives) in a Florida facility operated by Exactus, using equipment supplied by Canntab
  • Manufacturing is expected to begin near the end of Q1 2020
  • The agreements unlock a distribution channel to an estimated $1B+ CBD market in the U.S.*
  • Canntab’s hard pill formulations include extended release, immediate release and oral disintegrating tablets made with a variety of hemp-derived cannabinoids in exacting dosages
  • Canntab is also expected to manufacture  its growing line of products at the Florida facility on a white label basis, for distribution to U.S. and International third-party distributors and to end consumers
TORONTO, November 20th, 2019 – Canntab Therapeutics Limited (CSE:PILL.CN)(OTCQB:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab”), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a supply agreement (the “Supply Agreement”) and a non-exclusive distribution and profit sharing agreement (the “Distribution Agreement”, and together with the Supply Agreement, the “Agreements”) with Exactus Inc. (OTCMKTS: EXDI) (“Exactus”), a farm operator and manufacturer of hemp-derived phytocannabinoid products in the U.S.
Pursuant to the Supply Agreement, Canntab will purchase hemp-derived CBD oil resin from Exactus for use in its hard pill formulations, which are expected to include a variety of hemp-derived cannabinoids, such as Cannabidiol (CBD) and Cannabigerol (CBG), in instant release, extended release and oral disintegrating tablets with exacting dosages.  In connection with the entering into of the Agreements, Canntab is expected to equip a facility in Florida for the purpose of manufacturing advanced hemp-derived cannabinoid hard pill formulations for distribution throughout the U.S. The Supply Agreement is for an initial term of two years, and unless terminated in accordance with its terms, will automatically renew thereafter for additional two year terms.
Pursuant to the Distribution Agreement, Canntab and Exactus will share the gross profits derived from the sale of Canntab’s hard pill formulations, with the gross profits to be allocated in one of two ways, depending on the party originating such sales. The Distribution Agreement is for an initial term of two years, and unless terminated in accordance with its terms, may be renewed thereafter for two additional two-year terms.
The parties are currently working to finalize and enter into a separate sublease agreement, which is necessary to implement the parties’ arrangement under the Agreements. Under the sublease agreement, Exactus is expected to be responsible for building out and making improvements to the Florida facility while Canntab is expected to be responsible for providing equipment and expertise.
“Having known Jeff for over a decade, I was eager to connect Canntab’s game changing pharmaceutical solutions with Exactus’ high quality inputs,” explains Kevin J. Esval. Mr. Esval serves as an Independent Director at Exactus Inc., and is on the Board of Directors of multiple healthcare and specialty pharmaceutical companies. Mr. Esval continues, “Canntab has the future of medical cannabinoid solutions in a familiar pharmaceutical dosage form: a hard pill with timed release properties. These products are a perfect fit for Exactus as we are focused on developing high quality medical solutions that are currently unavailable in a market flooded with sub-optimal methods of delivery.”
Jeff Renwick, Chief Executive Officer of Canntab, said the logic of combining the two companies’ operations was compelling. “Our goal has been to develop a relationship with a trusted partner in the United States -one that allows us to bring our unique products to market in the U.S., and for our shareholders to benefit from that opportunity. I can confidently say that we have successfully achieved that goal, as our agreements with Exactus open the door to the growing CBD market in the United States. Our hard pill formulations will be one of the most advanced CBD solutions available, with extremely precise dosing, high bioavailability, timed release, and long shelf life. These are features that doctors, retailers and end consumers are searching for, all of which are covered by 13 patents pending in the United States, and Canada.”
“The supply and distribution agreements come at the perfect time during the evolution of our business strategy. The agreements will enable Canntab to bring their patent-pending hard pill formulations to the United States, adding to our suite of medically focused products and enhancing our position as the premier medically focused CBD solutions provider in the United States,” said Emiliano Aloi, President & CEO of Exactus. Mr. Aloi continues, “with the initiation of manufacturing expected to begin in the new year, we will leverage our growing distribution network to capture consumers looking for the next generation of medically focused products with maximum accuracy and total dose control.”
About Canntab Therapeutics Limited
Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace, formulated in multiple doses and time release combinations. Canntab’s proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication.
Canntab is a late stage applicant to Health Canada to be granted its Licensed Producer status: Cannabis (Processing-Standard), and Federal Sales (Medical). The Company intends to submit the final evidence package to Health Canada at the end of November 2019, and expects receipt of Licensed Producer Status in approximately 10 weeks thereafter.
Canntab is positioned to maintain high gross profit margins, due to its extensive inventory of machinery and equipment, some of which will be used for manufacturing in Florida. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.
About Exactus
Exactus Inc. is dedicated to introducing hemp-derived phytocannabinoid products that meet the highest standards of quality and traceability into mainstream consumer markets. The Company has made investments in farming and has over 200 acres of CBD-rich hemp in Southwest Oregon. The Company is introducing a range of consumer brands, such as Green Goddess Extracts™, Levor Collection, Phenologie, Paradise CBD and Exactus.
Hemp is a federally legal type of cannabis plant containing less than 0.3% THC (tetrahydrocannabinol), which is the psychoactive component of the cannabis plant. After over 40 years of prohibition, the Agricultural Improvement Act of 2018, known as the 2018 Farm Bill, legalized hemp at the federal level. Hemp production will be regulated by the United States Department of Agriculture (USDA) and the States. As a result, in 2019 hemp was generally removed from the Controlled Substances Act (CSA) and enforcement by the Drug Enforcement Administration (DEA).
FOR ADDITIONAL INFORMATION PLEASE CONTACT:
Canntab Therapeutics Limited
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
Frank Candido
Business Development
514-969-5530
Investor Relations:
Relations Publiques Paradox Inc.
Jean-Francois Meilleur
1-866-460-0408
Exactus Inc.
Andrew Johnson
Chief Strategy Officer
Exactus Inc.
509-999-9695

Cautionary Statements

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include, but are not limited to, information concerning the proposed execution of a sublease agreement, and the timing of the build out of the Florida facility, and expectations as to timing of manufacturing and distribution of hard pill formulations pursuant to or in connection with the Agreements. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward- looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that the parties will successfully negotiate and enter into the sublease agreement or complete the various transactions contemplated by the Agreements on the terms contemplated herein and therein, or at all, or that the timing anticipated by the parties to manufacture and distribute hard pill formulations will be achieved. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
* https://www.statista.com/statistics/760498/total-us-cbd-sales/

SOURCE Canntab Therapeutics Limited

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

Canntab Therapeutics Limited

For immediate release

2019_10_08

CANNTAB TO UTILIZE THE ADVANCED BOSS EXTRACTION SYSTEM FROM WORLD CLASS EXTRACTIONS TO FURTHER ITS OWN EXTRACTION CAPABILITIES

TORONTO, October 8th, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, today announced the signing of a binding Letter of Intent (“LOI”) to establish a joint venture (the “Joint Venture”) with World Class Extractions Inc. (CSE:PUMP) (“WCE”). Pursuant to the terms of the LOI, WCE will install certain extraction and processing systems (the “Systems”) at Canntab’s production facility in Markham, Ontario (the “Facility”). WCE is expected to begin delivery and installation of the Systems this month, and Canntab is expected to utilize the Systems upon receiving its Licensed Producer status from Health Canada.

As a late stage applicant, Health Canada approval under the Cannabis Act is at an advanced stage, which, once obtained, will allow Canntab to process high quality cannabis derivatives at the Facility. The Systems to be delivered and installed by WCE at the Facility include turnkey components from WCE’s portfolio of machines, including the BOSS next generation CO2 cannabis extraction system.

“We are excited to announce this strategic Joint Venture with Canntab and we are pleased that Canntab places their trust in our technology, people and our breadth of knowledge and experience in the cannabis and hemp extraction and processing space,” states Rosy Mondin, CEO of WCE. “We look forward to supporting Canntab’s growth as a global leader of research and production of hard-pill oral dosage therapeutic cannabis product forms.  Our WCE team has spent the last half-decade concentrating on R&D to bring leading technology and solutions to cannabis and hemp oil extraction. The Joint Venture will receive recurring revenue through its Toll Processing services and will increase WCE’s market presence.  Joint venture partnerships, such as the ones with FV Pharma inc. and Canntab, are key to the growth and success of WCE.”

Following execution of the definitive joint venture agreement (the “JV Agreement”), WCE and Canntab will each hold a 50% interest in the Joint Venture that will be established. The Joint Venture will acquire extraction Systems from WCE. The equipment will initially have an extraction and processing capacity of up 225 kilos of biomass per day, which could provide approximately 18 kilos of oil from high potency cannabis. This could then be used to create approximately 1,800,000 10mg tablets. Under the JV Agreement, the Systems will remain the property of WCE until all costs are recovered, at which time the equipment will become the property of the Joint Venture.

Canntab requires a consistent GMP grade of cannabis extracts as its active ingredients. While Canntab will continue to contract with third party suppliers such as its recent announcement with Heritage Cannabis Corp. on May 21, 2019, the Systems received from WCE will augment Canntab’s own extraction capacity.

“The availability of supply and unsustainable pricing within the extraction marketplace is a concern,” said Jeff Renwick, Co-Founder and CEO of Canntab.  Mr. Renwick continues, “having the BOSS and World-Class’ expertise will give Canntab the ability to control its own destiny by securing an ongoing supply for its manufacturing operations, where required. Multiple separation technologies including chromatography will also allow Canntab to separate the various cannabinoids and terpenoids, in order to diversify and expand its portfolio of cannabis based solid oral dosage forms.  With these elements, such as CBN and CBG, Canntab will be able to do further research into promising formulations that may approach a range of medical conditions.”

About Canntab Therapeutics Limited
Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace, formulated in multiple doses and time release combinations. Canntab’s proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication.
Canntab can produce these unique products with relatively minimal capital expenditure requirements therefore positioning the Company to maintain high gross profit margins due to its extensive inventory of machinery and equipment.
Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Forward Looking Statements

Neither the Canadian Securities Exchange (the “CSE“) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control.

 Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward- looking statements contained herein include, but are not limited to, information concerning the Joint Venture, including the proposed execution of a JV Agreement, the timing of WCE’s installation of the Systems at the Facility, the extraction and processing output of the Systems once installed, and expectations as to timing of the receipt of the Company’s licence from Health Canada. Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward- looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. In particular, there is no guarantee that the parties will successfully negotiate and enter into the JV Agreement or complete the various transactions contemplated thereby on the terms contemplated herein or at all, that the timing anticipated by the parties to deliver the Systems will be achieved, that the parties will realize the projected extraction and processing output of the Systems once installed. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.

SOURCE Canntab Therapeutics Limited

For further information: Canntab Therapeutics Limited, Jeffrey Renwick, Chief Executive Officer, +1 289.301.3812, jeff@canntab.ca; Frank Candido, Business Development, 514-969-5530, frank@canntab.ca; Investor Relations, Relations Publiques Paradox Inc., Jean-Francois Meilleur, 1-866-460-0408, jfmeilleur@paradox-pr.ca, https://www.paradox-pr.ca/

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

Canntab Therapeutics Limited

For immediate release

2019-08_15

CANNTAB RECEIVES INITIAL INDICATION OF PATENTABILITY FOR  IMMEDIATE RELEASE CANNABIDIOL FORMULATION

TORONTO, October 8th, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, is pleased to announce that it has received an initial assessment from the Geneva-based International Preliminary Report on Patentability (“IPRP”) for its Immediate Release Cannabidiol Formulation (the “Immediate Release Formulation”). The IPRP has indicated a positive finding of patentability, meaning that, in their opinion, Canntab’s formulation is not only patentable but also novel, non-obvious and useful. National filings have already been completed in the United States and internationally, and the international application has now been completed in Canada and Australia.

Although the opinions of the IPRP are not binding, many patent offices, including Canada’s for example, often defer to the IPRP. In fact, the Canadian office of the IPRP was also the international searching authority in this particular case, which bodes well for an eventual Canadian patent grant.
“This is a first and an important indication that our Immediate Release Cannabidiol Formulation is unique and patentable. It is our intention to build on this success as we continue to seek additional patents in Canada, United States and internationally. Our extensive portfolio of proprietary hard tablets is our core value proposition and we believe that we are well positioned to be the dominant player in hard tablet cannabinoid formulations world-wide,” states Jeff Renwick, co-founder and CEO of Canntab.
Canntab’s Extensive IP Portfolio – At the Core of Our Value Proposition
Canntab is a drug pharmaceutical company that has successfully created a line of patent-pending precision oral delivery hard tablets. Canntab’s proprietary technology and know-how enables it to convert THC and CBD oil into a nano-emulsified granulation, and ultimately into a hard pill format.
Canntab has filed 13 patents in Canada and United States that cover a range of processes and formulations it needs to create its precision oral delivery hard tablets, the future of medical cannabis. These patents include Canntab’s proprietary nano-emulsification technology, granulation process, methods of manufacturing, and covers it’s full line of precision oral delivery hard tablets including; Instant (Immediate) Release Tablets, Extended Release Tablets, Sustained Release Tablets, Bi-Layered (Modified Release) Tablets and Flash Melt Formulations.
As a late stage applicant to be a non-growing Licensed Producer and Processor, Canntab will be able to leverage its growing IP portfolio at its completed manufacturing facilities in both Markham and Cobourg.
About Canntab Therapeutics Limited
Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace, formulated in multiple doses and time release combinations. Canntab’s proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication.
Canntab can produce these unique products with relatively minimal capital expenditure requirements therefore positioning the Company to maintain high gross profit margins due to its extensive inventory of machinery and equipment.
Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Forward Looking Statements

Neither the Canadian Securities Exchange (the “CSE“) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Immediate Release Formulation being patented in the United States, Canada, Australia and internationally, and the likelihood of the Canadian patent having a higher chances of success as a result of the positive findings of the IPRP. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE Canntab Therapeutics Limited

For further information: Canntab Therapeutics Limited, Jeffrey Renwick, Chief Executive Officer, +1 289.301.3812, jeff@canntab.ca; Frank Candido, Business Development, 514-969-5530, frank@canntab.ca; Investor Relations, Relations Publiques Paradox Inc., Jean-Francois Meilleur, 1-866-460-0408, jfmeilleur@paradox-pr.ca, https://www.paradox-pr.ca/

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

Canntab Therapeutics Limited

For immediate release

2019-07-31

CANNTAB PROVIDES CORPORATE UPDATE

  • Commercial batch manufacturing of oil-filled gel capsules to begin in Cobourg, leading to a Health Canada request for authorization to begin full scale production and sale.
  • Construction nears completion in Markham, and Canntab intends to request a Health Canada inspection in early fall, to receive Licenced Producer (LP) status.
  • Cultivation at the hemp farm in Caledon advances with harvesting to begin next week.
  • A pharmacist and drug formulation specialist has been hired to assist with our product applications to Health Canada.

TORONTO, July 31st, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab“), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to provide an update on a number of significant developments, as well as a clear outline of what to expect in the coming months as edible products become legalized.

Near Term Revenue – Oil-Filled Gel Capsules

Utilizing a high-quality capsule machine that was recently installed in the Cobourg, Ontario facility that is shared with our partner FSD Pharma, Canntab will begin manufacturing commercial batches of oil-filled gel capsules with the intention of requesting Health Canada authorization to begin full scale production and sale. Once approved, these products will be distributed through our growing network of partners in October and beyond, pending Health Canada approval.

Health Canada Licenced Producer Status (LP)

The bulk of construction has been completed at the Company’s wholly-owned Markham, Ontario facility for the purpose of preparing for a Health Canada inspection, the final step before being granting Licenced Producer status. This coincides with Canntab’s engagement of Ample Organics, which will be providing a suite of services that are critical to our LP application.

Hemp Cultivation

Cultivation at the hemp farm in Caledon, Ontario advances with established plants that have thrived in an excellent growing season. Harvesting will begin next week and continue until the end of the season (at the beginning of October).

“We are excited to enter this new phase in our development, with manufacturing beginning in the Cobourg facility and construction nearing completion in Markham, we are taking the final steps necessary to bring our products to market. Oil-filled gel capsules will represent the first stream of revenue for Canntab before we are able to launch our flagship hard tablet products in October, pending Health Canada approval. Our line of solid oral dosage forms with timed release properties is expected to be the future of medical cannabis,” explains Jeff Renwick, Co-Founder and Chief Executive Officer of Canntab Therapeutics.

Additionally, Canntab has hired a pharmacist and drug formulation specialist, Erin Kofman. With over a decade of experience, Erin will assist with our application to Health Canada for approval of our various dosage forms. The Company will be compensating Erin through a paid salary and by granting 20,000 stock options. Each such option entitles the holder thereof to acquire one common share for a period of 3 years at an exercise price of $1.21 per common share. All 20,000 options vest immediately.

About Canntab Therapeutics Limited

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

Forward Looking Statements

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Standard Processing Licence application, the exportation of certain products into foreign markets, regulatory approvals relating to the Company’s medical cannabis business, and sales and distribution of cannabis-based products in a variety of regulated jurisdictions. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

SOURCE Canntab Therapeutics Limited

For further information: Canntab Therapeutics Limited, Jeffrey Renwick, Chief Executive Officer, +1 289.301.3812, jeff@canntab.ca; Frank Candido, Business Development, 514-969-5530, frank@canntab.ca; Investor Relations, Relations Publiques Paradox Inc., Jean-Francois Meilleur, 1-866-460-0408, jfmeilleur@paradox-pr.ca, https://www.paradox-pr.ca/

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019-05-30

CANNTAB SIGNS TERM SHEET WITH HERITAGE FOR PROCESSING HEMP FOR SALE OF CBD FILLED GELCAPS

– Canntab Makes Progress Towards Becoming Revenue-Generating in 2019 –

TORONTO, May 21, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab”), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has signed a term sheet with Heritage Cannabis Holdings Corp. (CSE:CANN) (“Heritage”) for the purpose of capsule manufacturing (the “Term Sheet”).

Under the Term Sheet, Canntab will provide hemp to Heritage’s subsidiary Purefarma Solutions (“Purefarma”) for the purpose of processing that hemp into high quality CBD oil. The oil will then be transformed into capsules by Canntab for Heritage, FSD Pharma Inc. (CSE:HUGE), and further white labelling opportunities.  The term sheet with Heritage will begin immediately, is open-ended, non-exclusive and may be cancelled by either party providing 120 days’ prior notice.

“This agreement with Canntab is a strategic fit for our growth as a contract service provider, aligns with our vision to operate in final product verticals and advances our offering in the medical cannabis sector.” states Clint Sharples, CEO of Heritage.

“After recently announcing the receipt of our cultivation licence for industrial hemp from Health Canada, we are immediately entering into important agreements to generate both short term and sustained revenue for the company. Our ability to encapsulate allows us to generate revenue without losing our long term focus on becoming the leading supplier of hard pill oral dose cannabinoid and terpene blends in the world,” states Jeff Renwick, co-founder and Chief Executive Officer of Canntab Therapeutics Limited.

Canntab’s application is currently “In Progress” to obtain a Cannabis Licence (Processing- Standard, Federal Sales – Medical) from Health Canada at its Markham, Ontario facility. Canntab currently operates out of Cobourg, Ontario with its strategic partner, FSD Pharma Inc. Upon receiving its Standard Processing Licence, Canntab intends to fully leverage both the Cobourg facility and its Markham facility for manufacturing and distribution through its growing network which currently includes Canada, Australia and Mexico.

About Canntab Therapeutics Limited

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids and terpenes in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

About Heritage Cannabis Holdings Corp.

Heritage is focused on becoming a vertically integrated cannabis provider that currently has two Health Canada approved licenced producers, through its subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated under the Cannabis Act Regulations. Working under these two licences, Heritage has two additional subsidiaries, Purefarma Solutions, which provides extraction services, and BriteLife Sciences which is focused on cannabis based medical solutions. Heritage as the parent company, is focused on providing the resources for its subsidiaries to advance their products or services to compete both domestically and internationally.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet that is licensed at its Ontario facility and expansion is currently underway.
FSD facilities sit on 70 acres of land with 40 acres primed for development with an expansion plan of up to 3,896,000 square feet by 2025.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017 and its Sale for Medical Purposes license on April 18, 2019. FV Pharma’s vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 289.301.3812

jeff@canntab.ca

 

Frank Candido,

Business Development,

514-969-5530,

frank@canntab.ca;

 

Investor Relations:

Relations Publiques Paradox Inc.,

Jean-Francois Meilleur,

1-866-460-0408,

jfmeilleur@paradox-pr.ca,

https://www.paradox-pr.ca/

 

Forward Looking Statements

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Standard Processing Licence application, the exportation of certain products into foreign markets, regulatory approvals relating to the Company’s medical cannabis business, and sales and distribution of cannabis-based products in a variety of regulated jurisdictions. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019-05-21

Canntab Receives Cultivation Licence for Industrial Hemp

Enables Canntab to Leverage Properties in Saskatchewan and Ontario to Cultivate High Quality Hemp for the Extraction of Cannabidiol (CBD)

Additionally, Canntab’s application is currently “In Progress” to obtain a Cannabis Licence (Processing- Standard, Federal Sales – Medical) from Health Canada at its Markham, Ontario facility.

TORONTO, May 21, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab”), the leading innovator in hard pill oral dose therapeutic cannabinoid and terpene blends, is pleased to announce that it has received a cultivation licence for industrial hemp from Health Canada pursuant to the Cannabis Act (Canada) (the “Hemp Licence“). Canntab intends to utilize the Hemp License to secure a substantial amount of hemp biomass that it will grow and cultivate for the extraction of cannabidiol (“CBD“) and to conduct research on high CBD hemp varieties, complementing the Company’s business plan to also manufacture CBD gel capsules for distribution through its partners in CanadaAustralia and Mexico. In addition, Canntab intends to use part of this CBD oil in its manufacturing of its suite of cannabis hard pills.

The Company has identified and secured two properties at which it intends to commence growing and cultivating industrial hemp. The first property, situated in Caledon, Ontario, will be operated in conjunction with the horticultural expertise of Thomas Elcome, with whom Canntab entered into supply agreements this past February (previously released on February 12th and 28th, 2019). The second property located near Regina, Saskatchewan, will allow Canntab, together with a prominent Saskatchewan farming corporation, to cultivate hemp. The two properties have an approximate total capacity of 560 acres, and Canntab has secured off-take agreements. Canntab intends to cultivate high quality hemp at both locations, leveraging the technical know how of Thomas Elcome. This hemp will then be used for extracting CBD and to conduct research into hemp varietals for the purpose of identifying high CBD strains to be used in future seasons.

Health Canada Cannabis Licence

In addition to the newly acquired Hemp Licence, Canntab’s application is currently “In Progress” to obtain a Cannabis Licence (Processing- Standard, Federal Sales – Medical) from Health Canada at its Markham, Ontario facility. Canntab currently operates out of Cobourg, Ontario with its strategic partner, FSD Pharma Inc. Upon receiving its Standard Processing Licence, Canntab intends to fully leverage both the Cobourg facility and its Markham facility for ongoing research and development, manufacturing and distribution through its growing network which currently includes CanadaAustralia and Mexico.

“Today’s news is another important milestone achieved by Canntab. We have now ensured a security of raw materials that we need for not only our oil filled gel capsules but ultimately our hard pill dosage forms. We also intend to apply for a Cannabis Drug License that will enable Canntab to conduct further research into making medical claims and develop and manufacture pharmaceutical grade cannabis derived dosage forms in a GMP environment,” stated Jeff Renwick, Chief Executive Officer of Canntab.

About Canntab

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 289.301.3812

jeff@canntab.ca

 

Frank Candido,

Business Development,

514-969-5530,

frank@canntab.ca

 

Investor Relations:

Relations Publiques Paradox Inc.,

Jean-Francois Meilleur,

1-866-460-0408,

jfmeilleur@paradox-pr.ca,

https://www.paradox-pr.ca/

 

Forward Looking Statements

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Standard Processing Licence application, the exportation of certain products into foreign markets, regulatory approvals relating to the Company’s medical cannabis business, and sales and distribution of cannabis-based products in a variety of regulated jurisdictions. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019-05-01

Canntab Therapeutics Now Trading on the OTCQX Best Market

– Canntab upgrades to the OTCQX Best Market for Better Investor Visibility –

TORONTO, May 1, 2019/ – Canntab Therapeutics Limited (CSE:PILL.CN) (OTCQX:CTABF) (FRA:TBF1.F) (the “Company” or “Canntab”), the Canadian leader in hard pill oral dose therapeutic cannabis, is pleased to announce that is has qualified for, and is now trading on, the OTCQX Best Market in the United States under the symbol “CTABF.”

“Historically, it’s been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. This move also coincides with Canntab reaching a major milestone in April which has opened the door for Canadian and international sales and white labeling,” explains Richard Goldstein, co-founder and Chief Financial Officer of Canntab.

“Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary processes,” says Jeff Renwick, co-founder and Chief Executive Officer of Canntab.

Canntab is well positioned in the emerging medical cannabis market with 13 patents pending in the United States and Canada covering a range of proprietary processes and formulations. In addition, the company is currently scaling up manufacturing at their Cobourg facility while moving through the regulatory processes with the intention of bringing a full suite of products to market in Canada and the United States, pending Health Canada approval.

About Canntab

Canntab Therapeutics Ltd. is a Canadian company engaged in the research and development of advanced, pharmaceutical-grade formulations of cannabinoids in a variety of timed-release dosages, including extended release, immediate release and flash melt. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Our proprietary hard pill cannabinoid formulations will provide doctors, patients and the general consumer with a medical grade solution with all the features you would expect from any prescription or over the counter medication. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQX Best Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 289.301.3812

jeff@canntab.ca

 

Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019-04-23

Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada

– Opens the Door for Canadian and International Sales and White Labeling –

Toronto, Ontario — April 23, 2019 — Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the “Company” or “Canntab”) is pleased to announce that by virtue of FSD Pharma Inc. (“FSD”), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a “sale for medical purposes” licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the “FSD Licence”), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD’s Health Canada approved facility in Cobourg, Ontario. In addition, the FSD Licence, when combined with an export permit, which FSD intends to acquire as soon as possible, may also allow Canntab to sell its products in foreign markets.

Jeffrey Renwick, Chief Executive Officer of Canntab, stated “We are thrilled that FSD has received its sales licence from Health Canada, and want to congratulate the entire FSD team on this significant milestone! Once we receive Health Canada approval for our capsules, we will begin white labeling for Canadian licensed producers, including FSD Pharma. Once FSD is able to export, Canntab will be able to sell its proposed products in foreign jurisdictions, including Australia and Mexico where we have agreements in place. We look forward to continuing to work closely with the team at FSD during this exciting new phase of our businesses.”

About Canntab

Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extendedrelease/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB Venture Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Jeffrey Renwick

Chief Executive Officer

+1 289.301.3812

jeff@canntab.ca

 

Frank Candido,

Business Development,

514-969-5530,

frank@canntab.ca

 

Investor Relations:

Relations Publiques Paradox Inc.,

Jean-Francois Meilleur,

1-866-460-0408,

jfmeilleur@paradox-pr.ca,

https://www.paradox-pr.ca/

 

Forward Looking Statements

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Standard Processing Licence application, the exportation of certain products into foreign markets, regulatory approvals relating to the Company’s medical cannabis business, and sales and distribution of cannabis-based products in a variety of regulated jurisdictions. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

Canntab Therapeutics Limited

For immediate release

2019-03_28

Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services

TORONTO, March 28, 2019 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE:PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox is a Montreal based investor relations consultancy firm that has been in business for 20 years, and is led by entrepreneur, Jean-Francois Meilleur. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.

Paradox will increase visibility towards the financial community by direct introduction, marketing to the investment community to identify potential investors, use of Paradox’s proprietary database and contacts for marketing purposes, organizing presentations with interested parties, and handling of incoming calls from shareholders and potential investors. Paradox’s extensive experience and large network provides full service approach to investor relations and it will provide creative, effective results-driven investor relations programs for Canntab.

The agreement is for a term of one year. Paradox will be paid $7,500 per month and will receive stock options exercisable into 300,000 common shares of the Company for a period of two years at a price of $1.00 per common share. The options will vest in four equal tranches in each quarter following the date hereof.

About Canntab

Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB Venture Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

 

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

Canntab Therapeutics Limited

For immediate release

2019-02-28

Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

TORONTO, Feb. 28, 2019 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.

On February 12, 2019, Canntab announced that it had entered into a three-way supply agreement with FSD, World Class and the Supplier to purchase up to 1,000 kg of the Supplier’s 2018 organic hemp crop. As with the 2018 hemp crop purchase, the Purchasers intend to extract CBD oil from the 2019-2024 organic hemp crops and process the oil into gel capsules and tablets at the FSD facility in Cobourg, Ontario. The anticipated purchase price for the 2019 crop is CAD $1.0 million plus applicable taxes. Of this amount, CAD $500,000 will be paid by the Purchasers as a loan to the Supplier in the form of equipment, to be paid back in the form of hemp.

“On February 19th, Canntab announced that we had begun to convert our interim facilities located within the FSD facility in Cobourg. This latest supply agreement will provide us with a significant amount of CBD oil over the next 5 years, which is required to manufacture our extensive suite of products for sale upon approval by Health Canada. This will include Canntab’s bi-layered hard pill consisting of both instant and extended release to be used in clinical trials to be conducted by Dr. Garbuz, subject to approval by the University of British Columbia Research Ethics Board,” stated Mr. Jeffrey Renwick, Chief Executive Officer of Canntab.

“We intend to take full advantage of the option to purchase up to the maximum total value of organic hemp from Mr. Elcome over the next 5 years beginning with the purchase of CAD $1.0 million of organic hemp in 2019. The hemp industry is expanding at an incredible rate and is expected to grow into a multi-billion dollar industry in North America,” added Dr. Raza Bokhari, Executive Co-chairman & Interim CEO. “Our processing license, received last week, allows FSD to work with Canntab and World Class to process the hemp product into CBD oil, a significant saleable product that can be converted into gel capsules and tablets. Once the edibles legislation is in place later this year in Canada, as we anticipate, FSD will be ready to process and supply the market.”

Michael McCombie, CEO of World Class, added, “This is yet another important supply agreement for World Class as it provides us with several years of raw hemp supply that we intend to process into CBD enriched oil and extracts at the FSD Facility. World Class’s continuous flow proprietary extraction technology is perfectly suited to process large scale hemp harvests into full spectrum oil and CBD, and we are preparing for the next stage of growth for our company as we await approval for our CSE listing. We will have our equipment in place and expect to be processing alongside FSD and Canntab in the coming few months.”

“This supply and loan agreement signed with FSD, Canntab and World Class extends our relationship over several years. The team at our company look forward to providing the highest-quality hemp to meet the needs of our partners in this venture,” said Mr. Thomas Elcome, President of 10975443 Canada Inc.

About Canntab

Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL, on the OTCQB Venture Market under the symbol CTABF, and on the Frankfurt Stock Exchange under the symbol TBF1.

About FSD Pharma

FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet available for production at its Ontario facility with an additional 220,000 square feet currently in development (with an estimated cost of $250 per square foot to be completed in 2019).

FSD facilities sit on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017. FV Pharma’s vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.

About World Class

World Class was incorporated under the Business Corporations Act (Ontario) on January 25, 2018 as a private company. World Class has developed a unique extraction process to produce quality, potent cannabis extracts. The extraction technology (the “WCE Technology”) uses ultrasound to effectively produce extracts from cannabis and hemp and isolate essential compounds found in plant material. The WCE Technology has a number of advantages over conventional extraction methods, including the ability to: (i) produce higher concentrated compounds; (ii) process larger volumes of cannabis or hemp; (iii) utilize undried cannabis or hemp in the process; (iv) utilize all parts of the cannabis or hemp plants, and, (v) reduce production time.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the company’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information contact:

Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

 

NOT FOR DISTRIBUTION TO PERSONS UNDER THE AGE OF 21

 


Canntab Therapeutics Limited

For immediate release

2019-02-19

Canntab Provides Corporate Update

  • Moving into FSD Pharma and FSD Processing License
  • Mackie Research Extension
  • Director Estate Planning Initiative
  • OTCQB under symbol CTABF

TORONTO, Feb. 19, 2019 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to provide an update on a number of significant developments, including that it has commenced converting a portion of its facility situated within the Health Canada approved facilities owned by FSD Pharma Inc. (“FSD Pharma”), which recently received its Standard Processing License, its previously announced financial advisory agreement with Mackie Research Capital Corporation (“Mackie Research”) has been extended, one of its directors, Vitor Fonseca, has advised the Company of his intention to transfer a portion of his equity through the exercise of options in the Company strictly for estate planning purposes to members of his family, and it it has begun trading on the OTCQB Venture Market.

Moving into FSD Pharma

The Company is pleased to announce that it has begun to convert its interim facilities (the “Canntab Facility”), formerly known as Grow Room #6, located within the Health Canada-approved facility owned and operated by FSD Pharma, which recently, through its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”), was issued a Standard Processing License from Health Canada (the “FSD Processing License”).

The FSD Processing License is a significant step towards FSD Pharma applying for a pre-sale inspection by Health Canada of its facilities. If FSD Pharma passes the pre-sale inspection, then it would likely receive its sales license from Health Canada shortly thereafter. Under the terms and conditions of Canntab’s collaboration and profit sharing agreement with FSD Pharma (the “Collaboration Agreement”), Canntab would then commence manufacturing its extensive suite of products under the supervision of FSD Pharma personnel, which likely paves the way for Canntab to commence generating revenue in the second quarter of 2019.

In addition, the Canntab Facility, combined with the FSD Processing License, will immediately allow the Company to manufacture its extensive suite of products for testing by Health Canada. Most importantly, this will include Canntab’s bi-layered hard pill consisting of both instant and extended release properties to be used in clinical trials being conducted by Dr. Garbuz, subject to approval by the University of British Columbia Research Ethics Board.

“Canntab moving into our Health Canada approved portion of our Cobourg facility is an important strategic achievement for FSD Pharma. I’m confident that Canntab’s oral delivery system will contribute immensely in superior solutions for patients and result in improved treatment outcomes,” stated Dr. Raza Bokhari, Executive Co-Chairman & Interim Chief Executive Officer of FSD Pharma.

Mackie Research Extension

Mackie Research will continue to act as financial advisor to the Company until April 30, 2019, providing a number of services, including, but not limited to, capital markets advisory, financial and operational analysis, and recommendations on strategic growth objectives.

As part of the compensation for its services during the Extension Period, the Company (i) will pay a monthly, non-refundable work fee of $14,000 to Mackie Research; and (ii) will grant 100,000 broker warrants (the “Mackie Warrants”) to Mackie Research. The Mackie Warrants will vest if, within six months of the date of their issuance, the Company’s common shares (“Common Shares”) have a daily volume weighted average trading price of more than $1.25 for 20 consecutive trading days. Each Mackie Warrant will entitle the holder thereof to purchase one common share in the capital of the Company (“Common Share”) at an exercise price of $1.02 for a period of 36 months.

Director Estate Planning Initiative

Vitor Fonseca, a Director of the Company, has informed the board of directors of the Company of his intention to exercise up to 300,000 stock options of the Company, and then to subsequently transfer up to half of the underlying Common Shares to immediate family members for the purpose of estate planning.

“These proposed transfers are strictly for the benefit of my estate planning objectives. My family has no intention to sell these shares at this time or in the near future. My family and I are here for the long-term. We could not be more satisfied with Canntab’s progress to date, and its prospects for the future,” said Mr. Fonseca.

Trading on the OTCQB Venture Market

The Company’s common shares (“Common Shares”) have begun trading on the OTCQB Venture Market under the symbol “CTABF”. This allows residents of the United States to purchase the Company’s stock more readily and can be used for contributions towards their 401(k) retirement savings plans, among other investment vehicles.

In addition, on April 20th, 2019, corresponding with its third year end, Canntab will begin trading on the OTCQX® Best Market. Companies found on OTCQX are said to be distinguished by the integrity of their operations and diligence with which they convey their qualifications. Canntab plans on exceeding these expectations by meeting high financial standards and following best practice corporate governance while demonstrating compliance with U.S. securities laws and being current and transparent with our disclosures.

“Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about hard pill oral dosage therapeutic cannabis,” said Jeff Renwick, Chief Executive Officer and a Director of Canntab.

About Canntab

Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent- pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL.

Forward-Looking Information

Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the company’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking statements include, but are not limited to, statements with respect to: the receipt by FSD Pharma of a license to sell cannabis, the subsequently planned manufacturing of Canntab’s suite of products, and the realization by Canntab of revenues in the second quarter of 2019 or at all. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. The material estimates and assumptions include the approval by Health Canada of the pre-sale inspection of FSD Pharma’s facilities, FSD Pharma subsequently assisting Canntab in manufacturing Canntab’s products in accordance with the terms and conditions of the Collaboration Agreement, and that the foregoing will enable Canntab to realize revenue by the second quarter of 2019. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, but are not limited to: general business, economic, competitive, political and social uncertainties; conditions imposed by Health Canada on FSD Pharma’s ability to sell cannabis; and delay or failure to receive all necessary regulatory approvals, including Health Canada’s. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking information contained in this press release is made as of the date hereof, and the company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information contact:
Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

 

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

 


 


Canntab Therapeutics Limited

For immediate release

2019-02-12 08:30 ET

Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

  • Canntab enters into 3-way supply agreement to purchase up to 1,000 kg of 2018 hemp crop
TORONTO, Feb. 12, 2019 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it has entered into a supply agreement (the “Agreement”) with FSD Pharma Inc. (“FSD Pharma”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.
Working alongside Canntab and World Class, FSD Pharma will extract CBD from the organic hemp obtained in the purchase order. The Purchasers will process the hemp flower into gel capsules and tablets at the FSD Pharma facility in Cobourg, Ontario. This facility is currently being transformed into a large hydroponic indoor cannabis production and processing facility, with multiple business units co-supporting each other and operating under a single roof to exploit economies of scale and operational efficiencies.
The Purchasers are in the process of executing a second agreement with the Supplier for the right and option to purchase the Supplier’s entire 2019 hemp crop and beyond.
“This is an exciting industry where we see tremendous growth potential for our company and is a great opportunity for Canntab to begin processing at the FSD Facility. Our collaboration and profit sharing agreement signed in September provides us with up to 10,000 square feet of space at the facility to build, install and manufacture a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers. This agreement allows our three complimentary companies to realize a common goal of creating value for our shareholders,” stated Mr. Jeffrey Renwick, Chief Executive Officer of Canntab.
“We look forward to working with Canntab, World Class and Mr. Elcome to obtain and produce high-quality hemp and hemp derived products in this burgeoning market where the opportunity is sizable across North America,” said Dr. Raza Bokhari, Executive Co-chairman & Interim CEO. “FSD Pharma recognizes the significant value and revenue potential that hemp holds in the cannabis industry and is confident in the excellence of Mr. Elcome’s product and the abilities of Canntab and World Class to produce.”
Michael McCombie, CEO of World Class, added, “World Class expects to begin installing our patent-pending proprietary extraction technology at the FSD Pharma’s Cobourg facility following our imminent listing on the CSE. This agreement will provide us with significant raw hemp supply for processing CBD enriched oil and extracts, which will be available for sale by World Class and/or conversion to gel capsules and tablets by Canntab.”
“FSD Pharma, Canntab and World Class are ideal companies to make the most of the 1,000 kg of organic hemp crop produced at my farm in Rockwood, Ontario,” said Mr. Thomas Elcome, President of 10975443 Canada Inc. “Preliminary testing has shown an average of 3% CBD and I am confident that we will be able to extract a very high quality and very valuable full spectrum CBD, and that this will be the beginning of a long and mutually beneficial relationship.”
About Canntab
Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL.
About FSD Pharma
FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company has 25,000 square feet available for production at its Ontario facility with an additional 220,000 square feet currently in development (with an estimated cost of $250 per square foot to be completed in 2019).
FSD Pharma facilities sit on 70 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.
FSD Pharma’s wholly-owned subsidiary, FV Pharma, is a licensed producer under the Cannabis Act and Regulations, having received its cultivation license on October 13, 2017. FV Pharma’s vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.
About World Class
World Class was incorporated under the Business Corporations Act (Ontario) on January 25, 2018 as a private company. World Class has developed a unique extraction process to produce quality, potent cannabis extracts. The extraction technology (the “WCE Technology”) uses ultrasound to effectively produce extracts from cannabis and hemp and isolate essential compounds found in plant material. The WCE Technology has a number of advantages over conventional extraction methods, including the ability to: (i) produce higher concentrated compounds; (ii) process larger volumes of cannabis or hemp; (iii) utilize undried cannabis or hemp in the process; (iv) utilize all parts of the cannabis or hemp plants, and, (v) reduce production time.
Forward-Looking Information
Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

For further information contact:
Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

 

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

 


Canntab Therapeutics Limited

For immediate release

2018-12-05 08:30 ET

Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets.

  • Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications.
  • The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets.
  • The study aims to show the potential for reduction or elimination of the use of opiates in patients, a major epidemic throughout North America.
  • The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.

TORONTO, Dec. 05, 2018 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, M.D. (Head of the Division of Lower Limb Reconstruction and Oncology of the Department of Orthopaedics at the University of British Columbia), subject to approval of the University of British Columbia where the proposed clinical trial will take place. The aim of the study is to examine and quantify the efficacy of Canntab products in decreasing the duration and quantity of postoperative use of opioid medications and in the management of preoperative pain. Dr. Garbuz shall be the Lead Investigator for the research study.

The Company is seeking approval from UBC to conduct with Dr. Garbuz as lead investigator, a randomized, double-blind, placebo-controlled clinical trials to determine the efficacy of Canntab’s products in helping effectively treat pain in patients. The study will look at the use of Canntab tablets to treat pain after knee replacement surgery. Patient safety and tolerability will also be assessed. Further, Canntab’s patent pending filing for addiction treatment therapy for opioids and other painkillers, and its specific proprietary tablet formulation, will be the starting point for the dosing delivery mechanism to be used in the study.

Canntab advises that it will create the tablets for the study in Coburg, Ontario with FSD Pharma, a Licensed Producer under the ACMPR in furtherance of their collaboration and license agreement dated September 17, 2018.

Zeeshan Saeed, President and Founder of FSD Pharma commented, “We are pleased that Canntab will be producing its tablets for this important study at our facility in Cobourg. The aim of this work is clearly in line with FSD Pharma’s direction and plans to develop pharmaceutical cannabinoid-based treatments for pain to counter the opioid crisis, including opioid abuse, dependence and overdose.”

Dr. Don Garbuz will be overseeing the study as lead investigator pursuant to a consulting agreement to be entered into between Canntab and Dr. Garbuz. Dr. Garbuz is a renowned orthopaedic surgeon and medical researcher, a Professor at the University of British Columbia and is credited with over 120 peer reviewed publications. Dr. Garbuz has been awarded the Hip Society Award for Best Research Paper four times; in 2009, 2011, 2013 and 2017.

“I am excited to be partnering with Canntab to look at conducting a trial that will analyze the efficacy of cannabis as a replacement for opioids, in postoperative care of orthopedic surgical patients undergoing hip/knee replacements at the UBC Hospital. This study will help advance our understanding of the potential effects of cannabis as a treatment for pain and will become the basis for conducting future cannabinoid and pain management clinical trials,” said Dr. Don Garbuz, M.D. “This important study which aims to help us better understand the potential impact of cannabis as an alternative for opioids, so that patients might face better outcomes.”

There is an opioid epidemic in the United States and Canada. The quality of life and addiction issues that stem from the widespread use of opioids is a major concern for individuals, communities, health care professionals and all levels of government. Most, if not all, patients undergoing total knee and hip arthroplasty use opioid medication to control their pain postoperatively. Their opioid usage is proving to be detrimental to overall health outcomes in some patients, and sometimes fatal. It is not uncommon for patients to misuse these medications after surgery, with nearly 5% of previously opiate-naïve patients becoming chronic abusers. A study from The Centers for Disease Control and Prevention (CDC) found that opiate prescriptions with medication supplies lasting greater than 8 days increased the likelihood of long-term abuse at 1 year (references below).

The financial arrangement calls for an initial upfront fee to create the clinical protocol while securing the participation and, required approvals of the clinical trial by UBC and the independent team comprising the Ethics Committee. Following those approvals, funds will be disbursed partially on certain milestones being achieved. The total cost of the study is estimated at approximately $600,000 with an anticipated time frame to complete of between 12 to 18 months.

About Canntab
Canntab Therapeutics is a Canadian cannabis oral dosage formulation company based in Markham, Ont., engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed patent-pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended-release/sustained-release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients. Canntab trades on the Canadian Securities Exchange under the symbol PILL.

For further information contact:
Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca

Forward Looking Statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Sources
Sabatino MJ, Kunkel ST, Ramkumar DB, Keeney BJ, Jevsevar DS. Excess Opioid Medication and Variation in Prescribing Patterns Following Common Orthopaedic Procedures. J Bone Joint Surg Am 2018;100:180-8.

Inacio MC, Hansen C, Pratt NL, Graves SE, Roughead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: a retrospective cohort study. BMJ Open 2016;6:e010664,2015-010664.

Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain 2016;157:1259-65.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

 


Canntab Therapeutics Limited

Canntab to Enter Medicinal Cannabis Market in Mexico

For immediate release

2018-10-31 08:45 ET

Letter of Intent with Labsco Promedic SA de CV of Mexico

  • Exclusive Licensing of Canntab’s sustained release tablets for distribution and sale in Mexico
  • Introduces Canntab and the Canntab product brands to the Mexican marketplace

TORONTO, Oct. 31, 2018 (GLOBE NEWSWIRE) — Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) today announced the signing of a non-binding Letter of Intent (the “LOI”) with Labsco Promedic SA de CV of Monterrey, Mexico (“Labsco”) for the establishment of a joint venture relationship for the sales & distribution of Canntab products in Mexico (the “Territory”) on an exclusive basis. Following the LOI, the parties will work together to establish and complete a formal joint venture relationship for an initial period of five years.

According to the LOI the following contributions to the proposed joint venture have been agreed to:

  • Labsco shall be responsible for funding and obtaining any and all regulatory, licencing or other such approvals for the importation and distribution of Canntab products in Mexico;
  • Labsco shall provide physical premises for the work of the joint venture;
  • Labsco shall be responsible for product distribution in Mexico;
  • Canntab shall license current Patents and Know-How, subject to completion of a License Agreement;
  • Canntab shall produce products in bulk from its Canadian facilities; and
  • Canntab shall provide products to the joint venture at an agreed price and margin.

The LOI is subject to completion of a Definitive Agreement. The Company anticipates completion of this formal agreement before the end of the year.

“Following several months of discussion including introductory due diligence, we are pleased to welcome Labsco and their team to the Canntab family. We are excited about the potential for our sustained release tablet formulations of cannabinoids in the Mexican market,” said Jeff Renwick, Canntab CEO. “Following our recently announced application to Health Canada to become a Licenced Producer under the ACMPR, and along with our production facility in collaboration with FSD Pharma, Canntab is building a significant international distribution network for its products. Labsco is the newest addition to this developing line of business for Canntab”.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed patent pending technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients.

For further information contact:

Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289.301.3812
jeff@canntab.ca
www.canntab.ca

Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

 


Canntab Therapeutics Limited

For immediate release

2018-10-18 08:30 ET

Canntab has submitted its application to Health Canada to become a Licensed Producer.

Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”) a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the “License”), and that it received confirmation from Health Canada that its application had been received. The License, if granted by Health Canada, would allow the Company to process cannabis products at its current production facility in Markham, Ontario with minimal additional capital expenditures as compared to a new purpose-built facility.

“We are excited to announce, as we enter into a new era of legalization, that Canntab has submitted its application to Health Canada to become a Licensed Producer. This is another step that enables Canntab to further diversify its manufacturing and distribution capabilities towards a world-wide rollout of its suite of precision oral dose delivery platforms for cannabis-based products,” said Jeff Renwick, CEO and a director of Canntab.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed patented technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. In doing so, Canntab has developed a suite of precision oral dose products that are unavailable elsewhere in the marketplace. Canntab’s primary focus is on providing cannabis-based products to medical professionals that can be used to deliver therapeutic treatments to their patients.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
Email: info@canntab.ca

Web: Canntab.ca

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canntab Therapeutics Limited

Canntab Therapeutics Limited

For immediate release

2018-10-01 06:55 ET – News Release

Canntab Enters LOI for Bi-Lateral Sales & Distribution and Cannabis Oil Supply

TORONTO, October 1, 2018 — Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”), today announced the completion of a non-binding Letter of Intent (the “LOI”) with NewCanna S.A.S of Bogota, Colombia (“NewCanna”) for the establishment of a significant bi-lateral relationship for the sale & distribution of Canntab’s products. The territory applicable to the agreement is the countries of Colombia, Chile, Paraguay and Spain, (collectively, the “Territory”). The agreement will grant NewCanna the right to sell and distribute certain Canntab exclusive proprietary products, and the right to utilize Canntab’s know-how and patents in the Territory only.

The LOI provides a 60-day period for the parties to complete a formal agreement, which will trigger a one-time, non-refundable License Fee of US $2-million payable to Canntab by NewCanna in consideration for the exclusive license to be granted by Canntab to NewCanna.

The formal agreement will establish:

  • Exclusive 5-year distribution agreement for Canntab’s oral sustained release tablet formulations in the Territory;
  • The supply of up to US$10-million of NewCanna cannabis oil to Canntab for which Canntab will place a deposit of US $1-million;
  • Agreement between the parties to work together to obtain the necessary regulatory and licensing approvals to implement the business requirements, including importation and exportation of materials;
  • Performance standards by NewCanna in each country covered by the agreement;
  • 50% / 50% profit sharing on the sales of products under the agreement;
  • Such other provisions as may be agreed to, and which would be customary in an agreement of this sort; and
  • Conditional upon the execution of a formal agreement encompassing the provisions of the LOI, payment of the US $2-million license fee and subject to any regulatory and exchange approvals, the Company will issue warrants to NewCanna to purchase up to 500,000 common shares of the Company at a price of $1.80 per common share for a period of two years.

The significance of this relationship is such that management of both Canntab and NewCanna will be devoting substantial effort to the completion of the formal agreement within the required timeline.  NewCanna would become a key supplier of raw materials for Canntab and on a cost basis which will be very favourable in comparison to other sources worldwide.

“We welcome this key development in our business plan and the opportunity to rapidly expand into the many potential markets for Canntab products worldwide. The wide variety of NewCanna’s cannabis strains will give us access to a full range of Cannabinoids and terpenoids to further our development pipeline.” said Jeff Renwick, Canntab CEO.  In conjunction with, our recently announced relationship with FSD Pharma and with our progressing work with Emblem Cannabis Corporation, I believe Canntab is poised to be the world leader in pharmaceutical grade, standardized tablet dosage of medicinal cannabis.”

Santiago Londono, the Founder and Chief Executive Officer of NewCanna, added “When carefully building a global network of cultivators and distribution channels in today’s fast-growing medicinal cannabis market it is imperative to identify the best possible pharma-grade manufacturing partners, this is why, after rigorously evaluating many other possible alliances, we have decided Canntab has the vision, infrastructure and knowledge that represents our best interest moving forward. Our main goal is to deliver the most responsible and precise dosage to every patient that trusts our brands, and we believe Canntab will be instrumental in achieving this objective.”

NewCanna, directly and through its existing partners;

  • has access to, or control over, four cultivation and extraction licenses
  • four additional licenses under application
  • over 3,000 hectares of cannabis production
  • a 32,000 square foot pharmaceutical-grade extraction facility capable of processing 5,000 tonnes of raw material per day – currently being upgraded to meet EU Good Manufacturing Practices (GMP) standards
  • Colombian oil-exportation license
  • operations within the Cannabis Free Trade Zone
  • genetic registration of more than 500 strains of cannabis and wide-ranging existing distribution.

 

Much of NewCanna’s direct and in-direct production is through local indigenous and peasant farmers licensed by the Government.  NewCanna is committed to the sustainable, good cultivation processes of the local growers and to supporting them in their own economic and business development.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis! Canntab trades on the Canadian Securities Exchange under the symbol PILL and on the Frankfurt Exchange under the symbol TBF1.

– 30 –

For further information contact:

Canntab Therapeutics Ltd.
Jeffrey Renwick
Chief Executive Officer
+1 289-301-3812
jeff@canntab.ca

NEWCANNA S.A.S.
Santiago Londono
Chief Executive Officer
+1 604-200-0440
Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE”) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

 

Canntab Therapeutics Limited

For immediate release

2018-09-25 09:00 ET – News Release

FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day.

Toronto, Ontario–(Newsfile Corp. – September 25, 2018) – FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE: PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment.

Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, “With this first delivery of manufacturing equipment at the Cobourg plant, we can begin the process of setting up our manufacturing space in collaboration with FSD Pharma. We expect manufacturing of our suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets to begin in earnest.”

Zeeshan Saeed, EVP and Director of FSD Pharma, added, “We are thrilled that Canntab is moving so quickly to set up its manufacturing facility at our Company. We too are moving quickly to build out our own 220,000 square feet of additional manufacturing capacity in Cobourg in collaboration with Auxly. This is truly an exciting time at FSD Pharma.”

FSD Pharma and Canntab previously announced the signing of a definitive collaboration and profit sharing agreement (the “Agreement”) effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act(the “License“), and will provide Canntab with space at its facility (the “FSD Facility“), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction“).

FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the “Canntab Premises“). Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers (the “Canntab Products“).

FSD Pharma and Canntab see tremendous opportunity in offering pharmaceutical quality cannabis based tablets, as many doctors are adverse to prescribing smoked cannabis as a solution to patients’ health concerns. The Canntab Premises are intended to be used to supply Canadian and International markets such as Australia and Germany, which legally allow cannabis. FSD Pharma will work with Canntab to prepare the necessary items to submit an application from Canntab to Health Canada to obtain the License, which will be attached to the Canntab Premises. In particular, FSD Pharma will assist with the following aspects of the application:

  1. drafting, or coordinating the drafting of, all application materials;
  2. sourcing all necessary third-party consultants required to prepare the application; and
  3. communicating with Health Canada throughout the application process.

In consideration of FSD Pharma’s services, Canntab will grant FSD Pharma certain royalty and profit sharing rights in connection with the sale of the Canntab Products. Canntab will provide FSD Pharma with 50% of the profits that Canntab receives on any retail sales of Canntab Products through channels that are established by FSD Pharma and FSD Pharma will be entitled to retain 50% of the profits on FSD Pharma’s sales of the Canntab Products. In addition, Canntab will pay FSD Pharma a royalty of 3.5% of Canntab’s sale price for all Canntab Products that are manufactured and sold from the Canntab Premises. Canntab may also purchase the oil that it requires for the Canntab Products from FSD Pharma.

About FSD Pharma

FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited

Richard Goldstein, CFO
Office: 416 957-6303
Email: info@canntab.ca

FSD Pharma Inc.

Thomas Fairfull, CEO & President
Email: thomas.fairfull@fvpharma.com

Neither the Canadian Securities Exchange nor its regulation services provider accept responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

 

Canntab Therapeutics Limited

For immediate release

9/18/2018 at 09:30 ET – News Release

CANNTAB SIGNS COLLABORATION AND PROFIT SHARING AGREEMENT WITH FSD PHARMA FOR PRODUCTION AND MARKET OF ORAL DOSE DELIVER PLATFORMS

Toronto, Ontario–(Newsfile Corp. – September 18, 2018) – Canntab Therapeutics Limited (CSE: PILL) (the “Company” or “Canntab“) is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the “Agreement) (OTC Pink: FSDDF) (FRA: 0K9) (“FSD Pharma“), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License“), and will provide Canntab with space at its facility (the “FSD Facility“), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction“).

FSD Pharma will provide Canntab with up to 10,000 square feet of space at the FSD Facility (the “Canntab Premises“). Canntab will build and install, at its expense, its own manufacturing facility within the larger FSD Facility that will operate in accordance with Good Manufacturing Practices, at which it will produce a suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets, and other types of cannabis-based products, including sleep aids and pain relievers (the “Canntab Products“).

Canntab and FSD Pharma see tremendous opportunity in offering pharmaceutical quality cannabis based tablets, as many doctors are adverse to prescribing smoked cannabis as a solution to patients’ health concerns. The Canntab Premises are intended to be used to supply Canadian and International markets such as Australia and Germany, which legally allow cannabis. FSD Pharma will work with Canntab to prepare the necessary items to submit an application from Canntab to Health Canada to obtain the License, which will be attached to the Canntab Premises. In particular, FSD Pharma will assist with the following aspects of the application:

  • Drafting, or coordinating the drafting of, all application materials;
  • Sourcing all necessary third-party consultants required to prepare the application; and
  • Communicating with Health Canada throughout the application process

In consideration of FSD Pharma’s services, Canntab will grant FSD Pharma certain royalty and profit sharing rights in connection with the sale of the Canntab Products. Canntab will provide FSD Pharma with 50% of the profits that Canntab receives on any retail sales of Canntab Products through channels that are established by FSD Pharma and FSD Pharma will be entitled to retain 50% of the profits on FSD Pharma’s sales of the Canntab Products. In addition, Canntab will pay FSD Pharma a royalty of 3.5% of Canntab’s sale price for all Canntab Products that are manufactured and sold from the Canntab Premises.  Canntab may also purchase the oil that it requires for the Canntab Products from FSD Pharma.

Mr. Jeffrey Renwick, Chief Executive Officer of Canntab, stated, “We are excited to begin work on our manufacturing space at the Cobourg facility and to collaborate with FSD Pharma to bring our expertise in the production of our suite of novel cannabis oral dose delivery platforms, including gel capsules and tablets to the cannabis medicinal market. Now that our definitive agreement is signed with FSD Pharma, we intend to work with the Company to move our application through the Health Canada process as swiftly and smoothly as possible”.

Thomas Fairfull, Chief Executive Officer of FSD Pharma, added, “The Company is pleased to welcome Canntab to our premises and to begin the process of offering through our agreement with Canntab a cannabis delivery platform consisting of pills and tablets that is the accepted norm among patients and doctors. We have complete faith in Jeff and his experienced team to deliver the best that the medicinal market demands. I look forward to an ongoing partnership with everyone involved as we continue to expand our offerings at our Cobourg facility”.

About Canntab

Canntab Therapeutics Limited is a Canadian cannabis oral dosage formulation company based in Markham Ontario, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids. Canntab has developed in-house technology to deliver standardized medical cannabis extract from selective strains in a variety of extended/sustained release pharmaceutical dosages for therapeutic use. Simply put, Canntab’s mission is to put the “Medical” into medicinal cannabis!

About FSD Pharma

FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma’s management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Canntab Therapeutics Limited
Richard Goldstein, CFO
Office: 416 957-6303
Email: info@canntab.ca

FSD Pharma Inc.
Thomas Fairfull, CEO
Email: thomas.fairfull@fvpharma.com

Forward Looking Statements

Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward looking statements. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be anticipated, estimated, or intended.

Neither the Canadian Securities Exchange (the “CSE“) nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

 

CONTACT US

Interested in what we do? Want to learn more about the opportunities we offer? Get in touch, enter your information and ask any questions you may have. We'll be sure to respond as soon as possible.

You can also reach us at Info@Canntab.ca

DISCLAIMER

This presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, or “will be taken”, “occur”, or “be achieved”. Forward-looking information is based on the opinions and estimates of management at the date the information is made, and is based on a number of assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including risks related to market and financing conditions as well as risks associated with the industries in which the Company operates, changes in project parameters as plans continue to be refined as well as other risk factors.  Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information contained herein.

Back To Top